Does NEO pay a dividend?

The cached stock data on this page does not show a positive dividend yield for NEO. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does NEO stock do?

Specialized oncology diagnostic laboratory providing testing services including cytogenetics, FISH, flow cytometry, and molecular testing via two segments: Clinical Services and Pharma Services.

What is NEO stock's price target?

This cached page does not contain a precise model fair value for NEO.

The TradeMates model verdict for NEO is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.

Is NEO a good dividend stock?

NEO is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

NEO (NEO) Stock Analysis

Q: Is NEO stock a good investment?

The cached TradeMates AI model rates NEO as HOLD with an investment score of 64/100. NeoGenomics is demonstrating a classic operational turnaround characterized by consistent earnings beats and improving margins. While GAAP net income is negative, the model favors the current price momentum and clinical segment growth. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Consistent earnings beats and raised EBITDA guidance signal an operational inflection point, though insider selling and high beta warrant caution.

Investment score: 64/100

NeoGenomics is demonstrating a classic operational turnaround characterized by consistent earnings beats and improving margins. While GAAP net income is negative, the model favors the current price momentum and clinical segment growth.

Peers

GRDN
PINC
ADUS
MD
AVAH

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
GRDN	48.22	11.75	1.78	25.10	—	0.04
PINC	60.35	2.74	0.03	1.51	—	0.09
ADUS	22.02	1.97	1.54	14.02	—	0.07
MD	12.98	2.53	1.14	9.39	—	0.09
AVAH	7.69	8.72	0.84	11.49	—	0.10

View the full interactive analysis